BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tian F, Feld JJ, Feng Z, Sander B, Wong WWL. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. J Hepatol 2022;77:947-56. [PMID: 35483535 DOI: 10.1016/j.jhep.2022.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 O'Brien SF, Reedman CN, Osiowy C, Bolotin S, Yi QL, Lourenço L, Lewin A, Binka M, Caffrey N, Drews SJ. Hepatitis B Blood Donor Screening Data: An Under-Recognized Resource for Canadian Public Health Surveillance. Viruses 2023;15. [PMID: 36851623 DOI: 10.3390/v15020409] [Reference Citation Analysis]
2 Zhuo C, Kong H, Yi K, Chi C, Zhang J, Chen R, Wang H, Wu C, Lao Y, Tao Y, Li M. Magnetic‐Activated Nanosystem with Liver‐Specific CRISPR Nonviral Vector to Achieve Spatiotemporal Liver Genome Editing as Hepatitis B Therapeutics. Adv Funct Materials 2023. [DOI: 10.1002/adfm.202210860] [Reference Citation Analysis]
3 Mitchell T, Nayagam JS, Dusheiko G, Agarwal K. Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries. JHEP Rep 2023;5:100623. [PMID: 36636709 DOI: 10.1016/j.jhepr.2022.100623] [Reference Citation Analysis]
4 Buti M, Craxi A, Foster GR, Maticic M, Negro F, Zeuzem S, Zoulim F. Viral hepatitis elimination: Towards a hepatitis-free world. J Hepatol 2022;77:1444-7. [PMID: 35907517 DOI: 10.1016/j.jhep.2022.06.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]